RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
RAPT Therapeutics, Inc. (Nasdaq: RAPT), focused on immunology and oncology therapies, announced a poster presentation for FLX475, its lead oncology drug candidate, at the 2023 ASCO annual meeting scheduled for June 2-6, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RAPT Therapeutics, Inc. (Nasdaq: RAPT), focused on immunology and oncology therapies, announced a poster presentation for FLX475, its lead oncology drug candidate, at the 2023 ASCO annual meeting scheduled for June 2-6, 2023. The poster titled "Clinical and Biological Activity of FLX475, an Oral CCR4 Antagonist, in Advanced Cancer" will be presented on June 3, 2023, from 8:00 a.m. to 11:00 a.m. ET. The abstract associated with the presentation will be released on May 25, 2023. RAPT is advancing two key drug candidates, RPT193 and FLX475, aimed at treating inflammatory diseases and cancer, respectively, showcasing their commitment to addressing significant unmet medical needs.
Positive
- Upcoming presentation at ASCO could enhance investor interest and visibility.
- Focus on FLX475 may strengthen RAPT's position in the oncology sector.
Negative
- None.
Details
News Market Reaction – RAPT
The recorded move for RAPT in the trading session of this news was -3.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present a poster on FLX475, its lead oncology drug candidate, at the 2023 American Society of Clinical Oncology (ASCO) annual meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL.
| Presentation details: | |
| Title: | Clinical and Biological Activity of FLX475, an Oral CCR4 Antagonist, in Advanced Cancer |
| Session Title: | Developmental Therapeutics—Immunotherapy |
| Session Date and Time: | Saturday, June 3, 2023; 8:00 a.m. - 11:00 a.m. ET |
| Abstract Number: | 2625 |
The abstract will be released on Thursday, May 25, 2023 at 5:00 p.m. ET on meetings.asco.org.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The company is also pursuing a range of targets that are in the discovery stage of development.
Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.